November 14, 2025
Aptose Reports Third Quarter 2025 Results
Tuspetinib Continues to Demonstrate Excellent Safety and Complete Responses in the TUSCANY Clinical Trial of Tuspetinib in AML Triple Drug…
Pharmaceuticals, Biotechnology and Life Sciences
Tuspetinib Continues to Demonstrate Excellent Safety and Complete Responses in the TUSCANY Clinical Trial of Tuspetinib in AML Triple Drug…
The 52-week symptom data reported for Cohort 6 patients is consistent with the long-term durability data previously reported from Cohort…
KUALA LUMPUR, Malaysia, Nov. 13, 2025 (GLOBE NEWSWIRE) — Bio Green Med Solution, Inc. (NASDAQ: BGMS, NASDAQ: BGMSP; “BGMS” or…
SOUTH SAN FRANCISCO, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) — Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology…
MALVERN, Pa., Nov. 13, 2025 (GLOBE NEWSWIRE) — TELA Bio, Inc. (“TELA”), a commercial-stage medical technology company focused on providing…
Four new patent applications filed that aim to expand the Curadigm Nanoprimer platform intellectual property portfolio and support an initial…
Presented new data at the Society of Immunotherapy for Cancer (SITC) annual meeting on CLD-401 protection from immune clearance after…
SOUTH SAN FRANCISCO, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) — Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation…
Announced completion of dose exploration portion of ORIC-944 Phase 1b clinical trial and presented data that continues to demonstrate potential…
RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2025 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a…